KR102262697B1 - 이소옥사졸릴-메톡시-니코틴산의 제조 방법 - Google Patents

이소옥사졸릴-메톡시-니코틴산의 제조 방법 Download PDF

Info

Publication number
KR102262697B1
KR102262697B1 KR1020207001557A KR20207001557A KR102262697B1 KR 102262697 B1 KR102262697 B1 KR 102262697B1 KR 1020207001557 A KR1020207001557 A KR 1020207001557A KR 20207001557 A KR20207001557 A KR 20207001557A KR 102262697 B1 KR102262697 B1 KR 102262697B1
Authority
KR
South Korea
Prior art keywords
formula
compound
salt
solvent
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207001557A
Other languages
English (en)
Korean (ko)
Other versions
KR20200008671A (ko
Inventor
파스칼 도트
스티븐 폴 한론
스테판 힐드브랜드
한스 이딩
앤드류 토마스
피우스 왈드마이어
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20200008671A publication Critical patent/KR20200008671A/ko
Application granted granted Critical
Publication of KR102262697B1 publication Critical patent/KR102262697B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/05—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in nitriles (3.5.5)
    • C12Y305/05001—Nitrilase (3.5.5.1)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020207001557A 2011-10-20 2012-10-17 이소옥사졸릴-메톡시-니코틴산의 제조 방법 Active KR102262697B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11185992.2 2011-10-20
EP11185992 2011-10-20
KR1020147013309A KR20140084209A (ko) 2011-10-20 2012-10-17 이소옥사졸릴-메톡시-니코틴산의 제조 방법
PCT/EP2012/070521 WO2013057123A1 (en) 2011-10-20 2012-10-17 Process for the preparation of isoxazolyl-methoxy-nicotinic acids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147013309A Division KR20140084209A (ko) 2011-10-20 2012-10-17 이소옥사졸릴-메톡시-니코틴산의 제조 방법

Publications (2)

Publication Number Publication Date
KR20200008671A KR20200008671A (ko) 2020-01-28
KR102262697B1 true KR102262697B1 (ko) 2021-06-11

Family

ID=47019026

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207001557A Active KR102262697B1 (ko) 2011-10-20 2012-10-17 이소옥사졸릴-메톡시-니코틴산의 제조 방법
KR1020147013309A Ceased KR20140084209A (ko) 2011-10-20 2012-10-17 이소옥사졸릴-메톡시-니코틴산의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147013309A Ceased KR20140084209A (ko) 2011-10-20 2012-10-17 이소옥사졸릴-메톡시-니코틴산의 제조 방법

Country Status (20)

Country Link
US (1) US8604062B2 (cg-RX-API-DMAC7.html)
EP (1) EP2768827B1 (cg-RX-API-DMAC7.html)
JP (1) JP5923174B2 (cg-RX-API-DMAC7.html)
KR (2) KR102262697B1 (cg-RX-API-DMAC7.html)
CN (1) CN103889978B (cg-RX-API-DMAC7.html)
AR (1) AR088358A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012321095B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014009266B1 (cg-RX-API-DMAC7.html)
CA (2) CA2850440C (cg-RX-API-DMAC7.html)
DK (1) DK2768827T3 (cg-RX-API-DMAC7.html)
ES (1) ES2613802T3 (cg-RX-API-DMAC7.html)
HU (1) HUE031276T2 (cg-RX-API-DMAC7.html)
IL (1) IL231645A (cg-RX-API-DMAC7.html)
MX (1) MX2014004688A (cg-RX-API-DMAC7.html)
MY (1) MY164880A (cg-RX-API-DMAC7.html)
PL (1) PL2768827T3 (cg-RX-API-DMAC7.html)
RU (1) RU2014118966A (cg-RX-API-DMAC7.html)
SG (1) SG11201401626UA (cg-RX-API-DMAC7.html)
SI (1) SI2768827T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013057123A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7403050B2 (ja) * 2017-08-28 2023-12-22 ユニバーシティ オブ メリーランド ボルチモア 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
AU2019286312B2 (en) 2018-06-13 2023-08-17 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as GABA A alpha5 PAM
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
GB202013765D0 (en) * 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
CN116854680A (zh) * 2022-03-28 2023-10-10 上海赛默罗生物科技有限公司 异噁唑-杂环类衍生物、药物组合物和用途
CN119265168B (zh) * 2024-11-05 2025-06-20 江南大学 一种新型腈水解酶及其在烟酸生物合成中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010112475A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Hydroxy-methyl isoxazole derivatives as gaba a modulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE315033T1 (de) 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
US6551804B2 (en) * 1999-07-12 2003-04-22 E. I. Du Pont De Nemours And Company Process for preparing 4-cyanopentanoic acid
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
UA82292C2 (uk) * 2004-04-14 2008-03-25 Пфайзер Продактс Инк. Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти)
CA2564429A1 (en) 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators
PL1802566T3 (pl) 2004-10-01 2009-05-29 Hoffmann La Roche Podstawione heksafluoroizopropanolem pochodne eteru
ATE485269T1 (de) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
JP2009508905A (ja) 2005-09-19 2009-03-05 エフ.ホフマン−ラ ロシュ アーゲー GABAAα5逆アゴニストとしてのイソオキサゾロ誘導体
CN101277952B (zh) 2005-10-11 2011-09-28 弗·哈夫曼-拉罗切有限公司 异*唑衍生物
RU2426731C2 (ru) 2005-12-23 2011-08-20 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазоло-4-ил-оксадиазола
US7618973B2 (en) 2007-12-04 2009-11-17 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
JP5301557B2 (ja) * 2007-12-04 2013-09-25 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリジン誘導体
JP2012040448A (ja) * 2008-11-14 2012-03-01 Yasutaka Sakamoto マイクロバブル発生装置
KR101354416B1 (ko) 2009-05-07 2014-02-19 에프. 호프만-라 로슈 아게 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010112475A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Hydroxy-methyl isoxazole derivatives as gaba a modulators

Also Published As

Publication number Publication date
PL2768827T3 (pl) 2017-05-31
US20130102778A1 (en) 2013-04-25
KR20140084209A (ko) 2014-07-04
ES2613802T3 (es) 2017-05-26
MY164880A (en) 2018-01-30
CN103889978B (zh) 2017-02-15
CA2850440C (en) 2021-05-04
BR112014009266A2 (pt) 2017-06-13
AR088358A1 (es) 2014-05-28
SG11201401626UA (en) 2014-05-29
MX2014004688A (es) 2014-05-28
EP2768827A1 (en) 2014-08-27
BR112014009266A8 (pt) 2020-04-22
US8604062B2 (en) 2013-12-10
IL231645A (en) 2016-09-29
AU2012321095A1 (en) 2013-05-09
CA2850440A1 (en) 2013-04-25
IL231645A0 (en) 2014-05-28
DK2768827T3 (en) 2017-02-13
JP2014530831A (ja) 2014-11-20
KR20200008671A (ko) 2020-01-28
WO2013057123A1 (en) 2013-04-25
NZ622214A (en) 2016-08-26
HUE031276T2 (hu) 2017-07-28
BR112014009266B1 (pt) 2021-05-04
SI2768827T1 (sl) 2017-04-26
AU2012321095B2 (en) 2015-08-20
CN103889978A (zh) 2014-06-25
EP2768827B1 (en) 2016-11-23
CA3112072A1 (en) 2013-04-25
JP5923174B2 (ja) 2016-05-24
CA3112072C (en) 2023-06-13
RU2014118966A (ru) 2015-11-27

Similar Documents

Publication Publication Date Title
DK2768827T3 (en) PROCEDURE FOR THE PREPARATION OF ISOXAZOLYL-METHOXY NICOTIC ACIDS
US9926313B2 (en) Imidazopyridine derivatives as modulators of TNF activity
US9650371B2 (en) Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
JP5918774B2 (ja) トリアゾール誘導体及びその神経障害に対する使用
US20120172355A1 (en) Aminodihydrothiazine derivatives substituted with a cyclic group
JP6815417B2 (ja) 新規化合物及びその薬理的に許容される塩
JPWO2007058305A1 (ja) シンナミド誘導体の製造方法
TW201607944A (zh) 雜芳基衍生物
JP2014530831A5 (cg-RX-API-DMAC7.html)
SG11202111162PA (en) Pyridin-3-yl derivatives
CN114075168A (zh) 一种吡唑衍生物及其在医药上的应用
NZ622214B2 (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
HK1193610B (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
HK1193610A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
Class et al. Patent application title: NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS Inventors: Steven Emiel Van Der Plas (Mechelen, BE) Hans Kelgtermans (Mechelen, BE) Sébastien Jean Jacques Cédric Dropsit Montover (Mechelen, BE) Sebastien Laurent Xavier Martina (Mechelen, BE) Martin James Inglis Andrews (Mechelen, BE)

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6